Determining the burden of fungal infections in Zimbabwe.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
24 06 2021
24 06 2021
Historique:
received:
12
02
2021
accepted:
08
06
2021
entrez:
25
6
2021
pubmed:
26
6
2021
medline:
8
7
2021
Statut:
epublish
Résumé
Zimbabwe currently faces several healthcare challenges, most notably HIV and associated infections including tuberculosis (TB), malaria and recently outbreaks of cholera, typhoid fever and COVID-19. Fungal infections, which are also a major public health threat, receive considerably less attention. Consequently, there is dearth of data regarding the burden of fungal diseases in the country. We estimated the burden of fungal diseases in Zimbabwe based on published literature and 'at-risk' populations (HIV/AIDS patients, survivors of pulmonary TB, cancer, chronic obstructive pulmonary disease, asthma and patients receiving critical care) using previously described methods. Where there was no data for Zimbabwe, regional, or international data was used. Our study revealed that approximately 14.9% of Zimbabweans suffer from fungal infections annually, with 80% having tinea capitis. The annual incidence of cryptococcal meningitis and Pneumocystis jirovecii pneumonia in HIV/AIDS were estimated at 41/100,000 and 63/100,000, respectively. The estimated prevalence of recurrent vulvovaginal candidiasis (RVVC) was 2,739/100,000. The estimated burden of fungal diseases in Zimbabwe is high in comparison to other African countries, highlighting the urgent need for increased awareness and surveillance to improve diagnosis and management.
Identifiants
pubmed: 34168204
doi: 10.1038/s41598-021-92605-1
pii: 10.1038/s41598-021-92605-1
pmc: PMC8225815
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
13240Subventions
Organisme : National Institute for Health Research
ID : Global Health Research programme (16/136/33)
Références
Denning, D. W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized. Philos. Trans. R. Soc. B Biol. Sci. 371, 20150468 (2016).
doi: 10.1098/rstb.2015.0468
Oladele, R. O. et al. Bridging the knowledge gap on mycoses in Africa: Setting up a Pan-African Mycology Working Group. Mycoses 63, 244–249. https://doi.org/10.1111/myc.13044 (2020).
doi: 10.1111/myc.13044
pubmed: 31829454
World Health Organization. Guidelines for the diagnosis, prevention and management of cryptococcal disease. 62 (2018).
Brown, G. D. et al. Hidden killers: Human fungal infections. Sci. Transl. Med. 4, 165rv113. https://doi.org/10.1126/scitranslmed.3004404 (2012).
doi: 10.1126/scitranslmed.3004404
Mortensen, K. L., Denning, D. W. & Arendrup, M. C. The burden of fungal disease in Denmark. Mycoses 58(Suppl 5), 15–21. https://doi.org/10.1111/myc.12383 (2015).
doi: 10.1111/myc.12383
pubmed: 26449502
Rodrigues, M. L. & Nosanchuk, J. D. Fungal diseases as neglected pathogens: A wake-up call to public health officials. PLoS Negl. Trop. Dis. 14, e0007964. https://doi.org/10.1371/journal.pntd.0007964 (2020).
doi: 10.1371/journal.pntd.0007964
pubmed: 32078635
pmcid: 7032689
Global Action Fund For Fungal Infections (GAFFI). https://www.gaffi.org/%20roadmap/ (2015). Accessed 16 Mar 2020
World Health Organization. Mycetoma, chromoblastomycosis and other deep mycoses, https://www.who.int/neglected_diseases/diseases/mycetoma/en/ (2020). Accessed 10 Nov 2020
Robertson, V. J. & Wright, S. A survey of tinea capitis in primary school children in Harare, Zimbabwe. J. Trop. Med. Hyg. 93, 419–422 (1990).
pubmed: 2270008
Gumbo, T. et al. Clinicopathological features of cutaneous histoplasmosis in human immunodeficiency virus-infected patients in Zimbabwe. Trans. R. Soc. Trop. Med. Hyg. 95, 635–636. https://doi.org/10.1016/s0035-9203(01)90103-8 (2001).
doi: 10.1016/s0035-9203(01)90103-8
pubmed: 11816437
Hakim, J. G. et al. Impact of HIV infection on meningitis in Harare, Zimbabwe: A prospective study of 406 predominantly adult patients. AIDS 14, 1401–1407. https://doi.org/10.1097/00002030-200007070-00013 (2000).
doi: 10.1097/00002030-200007070-00013
pubmed: 10930155
Ross, M. D. & Gelfand, M. Deep fungal infections in Rhodesia—A 10-year survey of histological material. Part I. Cent. Afr. J. Med. 24, 208–212 (1978).
pubmed: 719735
Ross, M. D. & Gelfand, M. Deep fungal infections in Rhodesia–a 10-year survey of histological material. Part II: mycetoma pseudomycetes phycomycosis mycotic abscess favus rhinosporidiosis histoplasmosis coccidioidomycosis. Cent. Afr. J. Med. 24, 231–236 (1978).
pubmed: 743734
Todd, C., Ray, S., Madzimbamuto, F. & Sanders, D. What is the way forward for health in Zimbabwe?. Lancet 375, 606–609. https://doi.org/10.1016/S0140-6736(09)61498-7 (2010).
doi: 10.1016/S0140-6736(09)61498-7
pubmed: 19828190
World Health Organization. Cholera – Zimbabwe. https://www.who.int/csr/don/05-october-2018-cholera-zimbabwe/en/ (2018). Accessed 12 July 2020
ProMED-mail. Typhoid fever—Zimbabwe: (HA). ProMED-mail 2018, Archive Number: 20200805.7648734. https://promedmail.org/promed-posts/ (2018). Accessed 31 July 2020
World Health Organization. Coronavirus disease (COVID-19) pandemic. https://www.who.int/emergencies/diseases/novel-coronavirus-2019 (2020). Accessed 20 Oct 2020
UNAIDS. https://www.unaids.org/en/resources/fact-sheet (2019). Accessed 21 July 2020
Jarvis, J. N. & Harrison, T. S. HIV-associated cryptococcal meningitis. AIDS 21, 2119–2129. https://doi.org/10.1097/QAD.0b013e3282a4a64d (2007).
doi: 10.1097/QAD.0b013e3282a4a64d
pubmed: 18090038
Park, B. J. et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23, 525–530 (2009).
pubmed: 19182676
doi: 10.1097/QAD.0b013e328322ffac
Malin, A. S. et al. Pneumocystis carinii pneumonia in Zimbabwe. Lancet 346, 1258–1261. https://doi.org/10.1016/s0140-6736(95)91862-0 (1995).
doi: 10.1016/s0140-6736(95)91862-0
pubmed: 7475717
Limper, A. H., Adenis, A., Le, T. & Harrison, T. S. Fungal infections in HIV/AIDS. Lancet. Infect. Dis 17, e334–e343. https://doi.org/10.1016/S1473-3099(17)30303-1 (2017).
doi: 10.1016/S1473-3099(17)30303-1
pubmed: 28774701
McLeod, D. T. et al. Pulmonary diseases in patients infected with the human immunodeficiency virus in Zimbabwe, Central Africa. Trans. R. Soc. Trop. Med. Hyg. 83, 694–697. https://doi.org/10.1016/0035-9203(89)90400-8 (1989).
doi: 10.1016/0035-9203(89)90400-8
pubmed: 2617633
Taylor, S. M. et al. Low prevalence of Pneumocystis pneumonia (PCP) but high prevalence of Pneumocystis dihydropteroate synthase (dhps) gene mutations in HIV-infected persons in Uganda. PLoS ONE 7, e49991. https://doi.org/10.1371/journal.pone.0049991 (2012).
doi: 10.1371/journal.pone.0049991
pubmed: 23166805
pmcid: 3500344
Prakash, H. & Chakrabarti, A. Global epidemiology of mucormycosis. J. Fungi 5, 26 (2019).
doi: 10.3390/jof5010026
Oladele, R. O., Ayanlowo, O. O., Richardson, M. D. & Denning, D. W. Histoplasmosis in Africa: An emerging or a neglected disease?. PLoS Negl. Trop. Dis. 12, e0006046–e0006046. https://doi.org/10.1371/journal.pntd.0006046 (2018).
doi: 10.1371/journal.pntd.0006046
pubmed: 29346384
pmcid: 5773084
Kosmidis, C. & Denning, D. W. The clinical spectrum of pulmonary aspergillosis. Thorax 70, 270. https://doi.org/10.1136/thoraxjnl-2014-206291 (2015).
doi: 10.1136/thoraxjnl-2014-206291
pubmed: 25354514
Obel, K. B. et al. Prevalence and determinants of asthma in adults in Kinshasa. PLoS One 12, e0176875. https://doi.org/10.1371/journal.pone.0176875 (2017).
doi: 10.1371/journal.pone.0176875
pubmed: 28464036
pmcid: 5413054
Sobel, J. D. Vulvovaginal candidosis. Lancet 369, 1961–1971 (2007).
pubmed: 17560449
doi: 10.1016/S0140-6736(07)60917-9
Gonçalves, B. et al. Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors. Crit. Rev. Microbiol. 42, 905–927 (2016).
pubmed: 26690853
doi: 10.3109/1040841X.2015.1091805
Tuli, S. S. Fungal keratitis. Clin. Ophthalmol. 5, 275–279. https://doi.org/10.2147/OPTH.S10819 (2011).
doi: 10.2147/OPTH.S10819
pubmed: 21468333
pmcid: 3065567
Ansari, Z., Miller, D. & Galor, A. Current thoughts in fungal keratitis: Diagnosis and treatment. Curr. Fungal Infect. Rep. 7, 209–218. https://doi.org/10.1007/s12281-013-0150-110.1007/s12281-013-0150-1 (2013).
doi: 10.1007/s12281-013-0150-110.1007/s12281-013-0150-1
pubmed: 24040467
pmcid: 3768010
Deorukhkar, S., Katiyar, R. & Saini, S. Epidemiological features and laboratory results of bacterial and fungal keratitis: A 5-year study at a rural tertiary-care hospital in western Maharashtra, India. Singap. Med. J. 53, 264–267 (2012).
Brown, L., Leck, A. K., Gichangi, M., Burton, M. J. & Denning, D. W. The global incidence and diagnosis of fungal keratitis. Lancet Infect. Dis. 29, e49–e57 (2020).
Zaraa, I. et al. Inflammatory Tinea capitis: A 12-year study and a review of the literature. Mycoses 56, 110–116. https://doi.org/10.1111/j.1439-0507.2012.02219.x (2013).
doi: 10.1111/j.1439-0507.2012.02219.x
pubmed: 22757767
Thakur, R. Tinea capitis in Botswana. Clin. Cosmet. Investig. Dermatol. 6, 37 (2013).
pubmed: 23386791
pmcid: 3563313
doi: 10.2147/CCID.S40053
Simpanya, M. F. A contribution to the study of tinea capitis in Lusaka, Zambia. East Afr. Med. J. 66, 269–275 (1989).
pubmed: 2743909
Morar, N., Dlova, N. C., Gupta, A. K. & Aboobaker, J. Tinea capitis in Kwa-Zulu Natal, South Africa. Pediatr. Dermatol. 21, 444–447 (2004).
pubmed: 15283786
doi: 10.1111/j.0736-8046.2004.21404.x
Sidat, M. M., Correia, D. & Buene, T. P. Tinea capitis among rural school children of the district of Magude, in Maputo province, Mozambique. Mycoses 49, 480–483 (2006).
pubmed: 17022765
doi: 10.1111/j.1439-0507.2006.01290.x
Bongomin, F. et al. Estimation of the burden of tinea capitis among children in Africa. Mycoses https://doi.org/10.1111/myc.13221 (2020).
doi: 10.1111/myc.13221
pubmed: 33251631
Baily, G. G., Robertson, V. J., Neill, P., Garrido, P. & Levy, L. F. Blastomycosis in Africa: Clinical features, diagnosis, and treatment. Rev. Infect. Dis. 13, 1005–1008. https://doi.org/10.1093/clinids/13.5.1005 (1991).
doi: 10.1093/clinids/13.5.1005
pubmed: 1962074
Brown, E. M. et al. Phylogenetic analysis reveals a cryptic species Blastomyces gilchristii, sp. nov. within the human pathogenic fungus Blastomyces dermatitidis. PLoS One 8, e59237. https://doi.org/10.1371/journal.pone.0059237 (2013).
doi: 10.1371/journal.pone.0059237
pubmed: 23533607
pmcid: 3606480
Schwartz, I. et al. Blastomycosis in Africa and the Middle East: A comprehensive review of reported cases and reanalysis of historical isolates based on molecular data. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciaa1100/5885166 (2020).
doi: 10.1093/cid/ciaa1100/5885166
pubmed: 32392330
pmcid: 8423473
Schwartz, I. S. et al. The estimated burden of fungal disease in South Africa. S. Afr. Med. J. 109, 885 (2019).
doi: 10.7196/SAMJ.2019.v109i11.13718
Badiane, A. S., Ndiaye, D. & Denning, D. W. Burden of fungal infections in Senegal. Mycoses 58(Suppl 5), 63–69. https://doi.org/10.1111/myc.12381 (2015).
doi: 10.1111/myc.12381
pubmed: 26449509
Oladele, R. O. & Denning, D. W. Burden of serious fungal infection in Nigeria. West Afr. J. Med. 33, 107–114 (2014).
pubmed: 25236826
Sustr, V., Foessleitner, P., Kiss, H. & Farr, A. Vulvovaginal candidosis: Current concepts, challenges and perspectives. J. Fungi 6, 267 (2020).
doi: 10.3390/jof6040267
Yano, J. et al. Current patient perspectives of vulvovaginal candidiasis: Incidence, symptoms, management and post-treatment outcomes. BMC Womens Health 19, 48–48. https://doi.org/10.1186/s12905-019-0748-8 (2019).
doi: 10.1186/s12905-019-0748-8
pubmed: 30925872
pmcid: 6441174
Mbizvo, E. M. et al. Association of herpes simplex virus type 2 with the human immunodeficiency virus among urban women in Zimbabwe. Int. J. STD AIDS 13, 343–348 (2002).
pubmed: 11972939
doi: 10.1258/0956462021925171
Kurewa, N. E. et al. The burden and risk factors of sexually transmitted infections and reproductive tract infections among pregnant women in Zimbabwe. BMC Infect. Dis. 10, 127. https://doi.org/10.1186/1471-2334-10-127 (2010).
doi: 10.1186/1471-2334-10-127
pubmed: 20492681
pmcid: 2881092
Sobel, J. D. Recurrent vulvovaginal candidiasis. Am. J. Obstet. Gynecol. 214, 15–21 (2016).
pubmed: 26164695
doi: 10.1016/j.ajog.2015.06.067
Aballéa, S. et al. Subjective health status and health-related quality of life among women with recurrent vulvovaginal candidosis (RVVC) in Europe and the USA. Health Qual. Life Outcomes 11, 169 (2013).
pubmed: 24119427
pmcid: 3815627
doi: 10.1186/1477-7525-11-169
Fukazawa, E. I. et al. Influence of recurrent vulvovaginal candidiasis on quality of life issues. Arch. Gynecol. Obstet. 300, 647–650. https://doi.org/10.1007/s00404-019-05228-3 (2019).
doi: 10.1007/s00404-019-05228-3
pubmed: 31270690
Djohan, V. et al. Recurrent vulvo-vaginal candidiasis in Abidjan (Côte d’Ivoire): Aetiology and associated factors. J. Mycol. Med. 29, 127–131. https://doi.org/10.1016/j.mycmed.2019.04.002 (2019).
doi: 10.1016/j.mycmed.2019.04.002
pubmed: 31010729
Dunaiski, C. M. & Denning, D. W. Estimated burden of fungal infections in Namibia. J. Fungi (Basel, Switzerland) 5, 75. https://doi.org/10.3390/jof5030075 (2019).
doi: 10.3390/jof5030075
Sacarlal, J. & Denning, D. W. Estimated burden of serious fungal infections in Mozambique. J. Fungi 4, 75 (2018).
doi: 10.3390/jof4030075
Kalua, K., Zimba, B. & Denning, D. W. Estimated burden of serious fungal infections in Malawi. J. Fungi 4, 61 (2018).
doi: 10.3390/jof4020061
Borgdorff, H. et al. The association between ethnicity and vaginal microbiota composition in Amsterdam, the Netherlands. PLoS ONE 12, e0181135. https://doi.org/10.1371/journal.pone.0181135 (2017).
doi: 10.1371/journal.pone.0181135
pubmed: 28700747
pmcid: 5507447
van de Wijgert, J. H. H. M. & Jespers, V. The global health impact of vaginal dysbiosis. Res. Microbiol. 168, 859–864. https://doi.org/10.1016/j.resmic.2017.02.003 (2017).
doi: 10.1016/j.resmic.2017.02.003
pubmed: 28257809
Koffi, D. et al. Estimates of serious fungal infection burden in Côte d’Ivoire and country health profile. J. Med. Mycol. 31, 101086. https://doi.org/10.1016/j.mycmed.2020.101086 (2021).
doi: 10.1016/j.mycmed.2020.101086
Usluogullari, B. et al. The role of human Dectin-1 Y238X gene polymorphism in recurrent vulvovaginal candidiasis infections. Mol. Biol. Rep. 41, 6763–6768. https://doi.org/10.1007/s11033-014-3562-2 (2014).
doi: 10.1007/s11033-014-3562-2
pubmed: 25008994
Mushi, M. F. et al. Oral candidiasis among African human immunodeficiency virus-infected individuals: 10 years of systematic review and meta-analysis from sub-Saharan Africa. J. Oral Microbiol. 9, 1317579 (2017).
pubmed: 28748027
pmcid: 5508360
doi: 10.1080/20002297.2017.1317579
Thanyasrisung, P. et al. Oral Candida carriage and immune status in Thai human immunodeficiency virus-infected individuals. J. Med. Microbiol. 63, 753–759 (2014).
pubmed: 24591706
doi: 10.1099/jmm.0.069773-0
Akinyemi, J. O. et al. Demographic and epidemiological characteristics of HIV opportunistic infections among older adults in Nigeria. Afr. Health Sci. 17, 315–321 (2017).
pubmed: 29062325
pmcid: 5637015
doi: 10.4314/ahs.v17i2.4
Rubaihayo, J. et al. Frequency and distribution patterns of opportunistic infections associated with HIV/AIDS in Uganda. BMC. Res. Notes 9, 501 (2016).
pubmed: 27927247
pmcid: 5142427
doi: 10.1186/s13104-016-2317-7
Garcia-Cuesta, C., Sarrion-Pérez, M.-G. & Bagán, J. V. Current treatment of oral candidiasis: A literature review. J. Clin. Exp. Dent. 6, e576–e582. https://doi.org/10.4317/jced.51798 (2014).
doi: 10.4317/jced.51798
pubmed: 25674329
pmcid: 4312689
Lashof, A. O. et al. An open multicentre comparative study of the efficacy, safety and tolerance of fluconazole and itraconazole in the treatment of cancer patients with oropharyngeal candidiasis. Eur. J. Cancer 40, 1314–1319 (2004).
doi: 10.1016/j.ejca.2004.03.003
Osaigbovo, I. I., Lofor, P. V. & Oladele, R. O. Fluconazole resistance among oral Candida isolates from people living with HIV/AIDS in a Nigerian tertiary hospital. J. Fungi 3, 69 (2017).
doi: 10.3390/jof3040069
Okonkwo, E., Alo, M., Nworie, O., Orji, J. & Agah, M. Prevalence of oral Candida albicans infection in HIV sero-positive patients in Abakaliki. Am. J. Life Sci. 1, 72–76 (2013).
Njunda, L. A. et al. Oral and urinary colonization of Candida species in HIV/AIDS patients in Cameroon. Basic Sci. Med. 2, 1–8 (2013).
Ambe, N. F. et al. The prevalence, risk factors and antifungal sensitivity pattern of oral candidiasis in HIV/AIDS patients in Kumba District Hospital, South West Region, Cameroon. Pan. Afr. Med. J. 36, 23–23. https://doi.org/10.11604/pamj.2020.36.23.18202 (2020).
doi: 10.11604/pamj.2020.36.23.18202
pubmed: 32774600
pmcid: 7392032
Nweze, E. I. & Ogbonnaya, U. L. Oral Candida isolates among HIV-infected subjects in Nigeria. J. Microbiol. Immunol. Infect. 44, 172–177 (2011).
pubmed: 21524610
doi: 10.1016/j.jmii.2011.01.028
Durski, K. N. et al. Cost-effective diagnostic checklists for meningitis in resource-limited settings. J. Acquir. Immune Defic. Syndr. 63, e101-108. https://doi.org/10.1097/QAI.0b013e31828e1e56 (2013).
doi: 10.1097/QAI.0b013e31828e1e56
pubmed: 23466647
pmcid: 3683123
Rhein, J. et al. Detrimental outcomes of unmasking cryptococcal meningitis with recent ART initiation. Open Forum Infect. Dis. 5, ofy122. https://doi.org/10.1093/ofid/ofy122 (2018).
doi: 10.1093/ofid/ofy122
pubmed: 30094292
pmcid: 6080052
Lakoh, S. et al. Prevalence and mortality of cryptococcal disease in adults with advanced HIV in an urban tertiary hospital in Sierra Leone: A prospective study. BMC Infect. Dis. 20, 141. https://doi.org/10.1186/s12879-020-4862-x (2020).
doi: 10.1186/s12879-020-4862-x
pubmed: 32059703
pmcid: 7023785
Mpoza, E. et al. Cryptococcal antigenemia in human immunodeficiency virus antiretroviral therapy-experienced ugandans with virologic failure. Clin. Infect. Dis. 71, 1726–1731. https://doi.org/10.1093/cid/ciz1069 (2019).
doi: 10.1093/cid/ciz1069
pmcid: 7755088
Ruffini, D. D. & Madhi, S. A. The high burden of Pneumocystis carinii pneumonia in African HIV-1-infected children hospitalized for severe pneumonia. AIDS 16, 105–112. https://doi.org/10.1097/00002030-200201040-00013 (2002).
doi: 10.1097/00002030-200201040-00013
pubmed: 11741168
Morris, A. et al. Current epidemiology of Pneumocystis pneumonia. Emerg. Infect. Dis. 10, 1713–1720. https://doi.org/10.3201/eid1010.030985 (2004).
doi: 10.3201/eid1010.030985
pubmed: 15504255
pmcid: 3323247
Ansari, N. A. et al. Pathology and causes of death in a series of human immunodeficiency virus-positive and-negative pediatric referral hospital admissions in Botswana. Pediatr. Infect. Dis. J. 22, 43–47 (2003).
pubmed: 12544408
doi: 10.1097/00006454-200301000-00013
World Health Organization. Tuberculosis. https://www.who.int/news-room/fact-sheets/detail/tuberculosis (2018, September 18). Accessed 18 Sept 2020
World Health Organization. The selection and use of essential in vitro diagnostics—TRS 1031. Report No. 1031, 373 (2021).
Oladele, R. et al. Chronic pulmonary aspergillosis as a cause of smear-negative TB and/or TB treatment failure in Nigerians. Int. J. Tuberc. Lung Dis. 21, 1056–1061 (2017).
pubmed: 28826456
doi: 10.5588/ijtld.17.0060
Ndarukwa, P., Chimbari, M. J. & Sibanda, E. Assessment of levels of asthma control among adult patients with asthma at Chitungwiza Central Hospital, Zimbabwe. Allergy Asthma Clin. Immunol. 16, 10. https://doi.org/10.1186/s13223-020-0405-7 (2020).
doi: 10.1186/s13223-020-0405-7
pubmed: 32042285
pmcid: 7001265
Denning, D. W. et al. Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study. Am. J. Respir. Crit. Care Med. 179, 11–18 (2009).
pubmed: 18948425
doi: 10.1164/rccm.200805-737OC
Agarwal, R. & Chakrabarti, A. Allergic bronchopulmonary aspergillosis in asthma: Epidemiological, clinical and therapeutic issues. Future Microbiol. 8, 1463–1474 (2013).
pubmed: 24199804
doi: 10.2217/fmb.13.116
Agarwal, R. et al. Diagnostic performance of various tests and criteria employed in allergic bronchopulmonary aspergillosis: A latent class analysis. PLoS One 8, e61105 (2013).
pubmed: 23593402
pmcid: 3625190
doi: 10.1371/journal.pone.0061105
Rapeport, W. G., Ito, K. & Denning, D. W. The role of antifungals in the management of patients with severe asthma. Clin. Transl. Allergy 10, 46. https://doi.org/10.1186/s13601-020-00353-8 (2020).
doi: 10.1186/s13601-020-00353-8
pubmed: 33292524
pmcid: 7646070
Agarwal, R. et al. Allergic bronchopulmonary aspergillosis. Indian J. Med. Res. 151, 529–549. https://doi.org/10.4103/ijmr.IJMR_1187_19 (2020).
doi: 10.4103/ijmr.IJMR_1187_19
pubmed: 32719226
pmcid: 7602921
Denning, D. W. et al. Fungal allergy in asthma—State of the art and research needs. Clin. Transl. Allergy 4, 14 (2014).
pubmed: 24735832
pmcid: 4005466
doi: 10.1186/2045-7022-4-14
Chepchirchir, A., Bii, C. & Ndinya-Achola, J. Dermatophyte infections in primary school children in Kibera slums of Nairobi. East Afr. Med. J. 86, 59–68 (2009).
pubmed: 19894469
doi: 10.4314/eamj.v86i2.46934
Emele, F. & Oyeka, C. Tinea capitis among primary school children in Anambra state of Nigeria. Mycoses 51, 536–541 (2008).
pubmed: 18422917
doi: 10.1111/j.1439-0507.2008.01507.x
Nweze, E. & Eke, I. Dermatophytes and dermatophytosis in the eastern and southern parts of Africa. Med. Mycol. 56, 13–28 (2018).
pubmed: 28419352
doi: 10.1093/mmy/myx025
Kechia, F. A. et al. Epidemiology of Tinea capitis among school-age children in Meiganga, Cameroon. J. Mycol. Med. 24, 129–134. https://doi.org/10.1016/j.mycmed.2013.12.002 (2014).
doi: 10.1016/j.mycmed.2013.12.002
pubmed: 24746727
Moto, J. N., Maingi, J. M. & Nyamache, A. K. Prevalence of Tinea capitis in school going children from Mathare, informal settlement in Nairobi, Kenya. BMC. Res. Notes 8, 274. https://doi.org/10.1186/s13104-015-1240-7 (2015).
doi: 10.1186/s13104-015-1240-7
pubmed: 26116079
pmcid: 4483201
Emmanuel, P., Dumre, S. P., John, S., Karbwang, J. & Hirayama, K. Mycetoma: A clinical dilemma in resource limited settings. Ann. Clin. Microbiol. Antimicrob. 17, 35–35. https://doi.org/10.1186/s12941-018-0287-4 (2018).
doi: 10.1186/s12941-018-0287-4
pubmed: 30097030
pmcid: 6085652
Abbas, M. et al. The disabling consequences of Mycetoma. PLoS Negl. Trop. Dis. 12, e0007019 (2018).
pubmed: 30532253
pmcid: 6312340
doi: 10.1371/journal.pntd.0007019
Bakhiet, S. M. et al. A holistic approach to the mycetoma management. PLoS Negl. Trop. Dis. 12, e0006391–e0006391. https://doi.org/10.1371/journal.pntd.0006391 (2018).
doi: 10.1371/journal.pntd.0006391
pubmed: 29746460
pmcid: 5944909
Ndiaye, B., Develoux, M., Langlade, M. & Kane, A. in Annales de Dermatologie et de Venereologie. 161–165.
Dieng, M., Niang, S., Diop, B. & Ndiaye, B. Actinomycétomes au Sénégal. Étude de 90 cas. Bull. Soc. Pathol. Exot. 98, 14–17 (2005).
Dieng, M., Sy, M., Diop, B., Niang, S. & Ndiaye, B. in Annales de Dermatologie et de Venereologie. 16–19.
Develoux, M., Vetter, J., Audoin, J. & Treguer, J. 63 cases of mycetoma in the Niger Republic (etiological study based on histopathology). Bulletin de la Societe de Pathologie Exotique et de ses Filiales 78, 574–584 (1985).
pubmed: 4085097
Destombes, P., Mariat, F., Rosati, L. & Segretain, G. Mycetoma in Somalia-results of a survey done from 1959 to 1964. Acta Trop. 34, 355–373 (1977).
pubmed: 23657
Ahmed, A. O. et al. Mycetoma caused by Madurella mycetomatis: A neglected infectious burden. Lancet. Infect. Dis 4, 566–574 (2004).
pubmed: 15336224
doi: 10.1016/S1473-3099(04)01131-4
Ashraf, N. et al. Re-drawing the maps for endemic mycoses. Mycopathologia https://doi.org/10.1007/s11046-020-00431-2 (2020).
doi: 10.1007/s11046-020-00431-2
pubmed: 32040709
pmcid: 7416457
Hayes, G. E. & Denning, D. W. Frequency, diagnosis and management of fungal respiratory infections. Curr. Opin. Pulm. Med. 19, 259–265. https://doi.org/10.1097/MCP.0b013e32835f1ad1 (2013).
doi: 10.1097/MCP.0b013e32835f1ad1
pubmed: 23411576
Journal, T. P. https://www.pharmaceutical-journal.com/news-and-analysis/opinion/correspondence/pharmacists-should-make-themselves-familiar-with-the-antifungal-drug-interactions-database/20208143 (2020).
Tseng, A. & Foisy, M. Important drug–drug interactions in HIV-infected persons on antiretroviral therapy: An update on new interactions between HIV and non-HIV drugs. Curr. Infect. Dis. Rep. 14, 67–82. https://doi.org/10.1007/s11908-011-0229-1 (2012).
doi: 10.1007/s11908-011-0229-1
pubmed: 22125049
Vadlapatla, R. K., Patel, M., Paturi, D. K., Pal, D. & Mitra, A. K. Clinically relevant drug–drug interactions between antiretrovirals and antifungals. Expert Opin. Drug Metab. Toxicol. 10, 561–580. https://doi.org/10.1517/17425255.2014.883379 (2014).
doi: 10.1517/17425255.2014.883379
pubmed: 24521092
pmcid: 4516223
Ministry of Health and Family Welfare. Vol. 5 (The National Drug and Therapeutics Policy Advisory Committe (NDTPAC), Ministry of Health and Child Welfare, Republic of Zimbabwe, 2006).
Osakunor, D. N. M., Sengeh, D. M. & Mutapi, F. Universal health coverage in africa: Coinfections and comorbidities. Trends Parasitol. 34, 813–817 (2018).
pubmed: 30057348
doi: 10.1016/j.pt.2018.07.002
Africa, C. W. J. & Abrantes, P. M. D. S. Candida antifungal drug resistance in sub-Saharan African populations: A systematic review. F1000Research 5, 2832–2832. https://doi.org/10.12688/f1000research.10327.2 (2016).
doi: 10.12688/f1000research.10327.2
pubmed: 28154753
Bii, C. C. et al. Antifungal drug susceptibility of Cryptococcus neoformans from clinical sources in Nairobi, Kenya. Mycoses 50, 25–30 (2007).
pubmed: 17302744
doi: 10.1111/j.1439-0507.2006.01293.x
Wang, F.-J., Dai Zhang, Z.-H.L., Wu, W.-X., Bai, H.-H. & Dong, H.-Y. Species distribution and in vitro antifungal susceptibility of vulvovaginal Candida isolates in China. Chin. Med. J. 129, 1161 (2016).
pubmed: 27174323
pmcid: 4878160
doi: 10.4103/0366-6999.181964
Özenci, V. et al. Estimated burden of fungal infections in Sweden. Mycoses 62, 1043–1048. https://doi.org/10.1111/myc.12981 (2019).
doi: 10.1111/myc.12981
pubmed: 31376228
Corley, A. G., Thornton, C. P. & Glass, N. E. The role of nurses and community health workers in confronting neglected tropical diseases in Sub-Saharan Africa: A systematic review. PLoS Negl. Trop. Dis. 10, e0004914. https://doi.org/10.1371/journal.pntd.0004914 (2016).
doi: 10.1371/journal.pntd.0004914
pubmed: 27631980
pmcid: 5025105
Midzi, N. et al. Distribution of schistosomiasis and soil transmitted helminthiasis in Zimbabwe: Towards a national plan of action for control and elimination. PLoS Negl. Trop. Dis. 8, e3014. https://doi.org/10.1371/journal.pntd.0003014 (2014).
doi: 10.1371/journal.pntd.0003014
pubmed: 25121489
pmcid: 4133179
Deribe, K. et al. Developing and validating a clinical algorithm for the diagnosis of podoconiosis. Trans. R. Soc. Trop. Med. Hyg. 114, 916–925. https://doi.org/10.1093/trstmh/traa074 (2020).
doi: 10.1093/trstmh/traa074
pubmed: 33174588
pmcid: 7738664
Infections, G. A. F. F. F. Publications. https://www.gaffi.org/media/academic-papers/ (2020). Accessed 13 Sept 2020
Sabino, R. et al. Serious fungal infections in Portugal. Eur. J. Clin. Microbiol. Infect. Dis. 36, 1345–1352. https://doi.org/10.1007/s10096-017-2930-y (2017).
doi: 10.1007/s10096-017-2930-y
pubmed: 28188492
Nations, U. World Population Prospects. https://population.un.org/wpp/ (2019). Accessed 21 July 2020
Education, L. I. F. Fungal Infections. < http://www.life-worldwide.org/fungal-diseases (2020). Accessed 20 Sept 2020
Ocansey, B. K. et al. Estimated burden of serious fungal infections in Ghana. J. Fungi (Basel, Switzerland) 5, 38. https://doi.org/10.3390/jof5020038 (2019).
doi: 10.3390/jof5020038
Guyatt, G. H. et al. What is “quality of evidence” and why is it important to clinicians?. BMJ 336, 995–998. https://doi.org/10.1136/bmj.39490.551019.be (2008).
doi: 10.1136/bmj.39490.551019.be
pubmed: 18456631
pmcid: 2364804
Lortholary, O. et al. Epidemiological trends in invasive aspergillosis in France: The SAIF network (2005–2007). Clin. Microbiol. Infect. 17, 1882–1889 (2011).
pubmed: 21668573
doi: 10.1111/j.1469-0691.2011.03548.x
Antinori, S. et al. Trends in the postmortem diagnosis of opportunistic invasive fungal infections in patients with AIDS: A retrospective study of 1,630 autopsies performed between 1984 and 2002. Am. J. Clin. Pathol. 132, 221–227 (2009).
pubmed: 19605816
doi: 10.1309/AJCPRAAE8LZ7DTNE
Guinea, J. et al. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. Clin. Microbiol. Infect. 16, 870–877 (2010).
pubmed: 19906275
doi: 10.1111/j.1469-0691.2009.03015.x
Yan, X. et al. Clinical characteristics of 45 patients with invasive pulmonary aspergillosis: Retrospective analysis of 1711 lung cancer cases. Cancer Interdiscip. Int. J. Am. Cancer Soc. 115, 5018–5025 (2009).
Arendrup, M. C. Epidemiology of invasive candidiasis. Curr. Opin. Crit. Care 16, 445–452 (2010).
pubmed: 20711075
doi: 10.1097/MCC.0b013e32833e84d2
Montravers, P. et al. A multicentre study of antifungal strategies and outcome of Candida spp. peritonitis in intensive-care units. Clin. Microbiol. Infect. 17, 1061–1067 (2011).
pubmed: 20825438
doi: 10.1111/j.1469-0691.2010.03360.x
Denning, D. W., Pleuvry, A. & Cole, D. C. Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. Med. Mycol. 51, 361–370 (2013).
pubmed: 23210682
doi: 10.3109/13693786.2012.738312
Rajasingham, R. et al. Global burden of disease of HIV-associated cryptococcal meningitis: An updated analysis. Lancet. Infect. Dis 17, 873–881 (2017).
pubmed: 28483415
pmcid: 5818156
doi: 10.1016/S1473-3099(17)30243-8
Denning, D. W., Kneale, M., Sobel, J. D. & Rautemaa-Richardson, R. Global burden of recurrent vulvovaginal candidiasis: A systematic review. Lancet. Infect. Dis 18, e339–e347. https://doi.org/10.1016/S1473-3099(18)30103-8 (2018).
doi: 10.1016/S1473-3099(18)30103-8
pubmed: 30078662
Bitar, D. et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997–2006. Emerg. Infect. Dis. 15, 1395–1401. https://doi.org/10.3201/eid1509.090334 (2009).
doi: 10.3201/eid1509.090334
pubmed: 19788806
pmcid: 2819884
Evaluation, I. f. H. M. a. GBD Compare | IHME Viz Hub, https://vizhub.healthdata.org/gbd-compare/ (2017). Accessed 31 July 2020
Ssemwanga, D. et al. Update on HIV-1 acquired and transmitted drug resistance in Africa. AIDS Rev. 17, 3–20 (2015).
pubmed: 25427100
Musafiri, S. et al. Prevalence of atopy, asthma and COPD in an urban and a rural area of an African country. Respir. Med. 105, 1596–1605. https://doi.org/10.1016/j.rmed.2011.06.013 (2011).
doi: 10.1016/j.rmed.2011.06.013
pubmed: 21783353
Hammond, E. E., McDonald, C. S., Vestbo, J. & Denning, D. W. The global impact of Aspergillus infection on COPD. BMC Pulm. Med. 20, 1–10 (2020).
doi: 10.1186/s12890-020-01259-8
van Gemert, F. et al. Prevalence of chronic obstructive pulmonary disease and associated risk factors in Uganda (FRESH AIR Uganda): A prospective cross-sectional observational study. Lancet Glob. Health 3, e44–e51 (2015).
pubmed: 25539969
doi: 10.1016/S2214-109X(14)70337-7
World Health Organization. Diabetes country profiles. https://www.who.int/diabetes/country-profiles/zwe_en.pdf?ua=1 (2016). Accessed 10 Oct 2020
Observatory, G. C. Zimbabwe. https://gco.iarc.fr/ (2018). Accessed 16 Mar 2020
Denning, D. W., Pleuvry, A. & Cole, D. C. Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. Bull. World Health Organ. 89, 864–872 (2011).
pubmed: 22271943
pmcid: 3260898
doi: 10.2471/BLT.11.089441
Smith, N. & Denning, D. Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. Eur. Respir. J. 37, 865–872 (2011).
pubmed: 20595150
doi: 10.1183/09031936.00054810
Benatar, S., Keen, G. & Naude, W. D. T. Aspergillus hypersensitivity in asthmatics in Cape Town. Clin. Exp. Allergy 10, 285–291 (1980).
doi: 10.1111/j.1365-2222.1980.tb02109.x
Matee, M., Scheutz, F. & Moshy, J. Occurrence of oral lesions in relation to clinical and immunological status among HIV-infected adult Tanzanians. Oral Dis. 6, 106–111 (2000).
pubmed: 10702788
doi: 10.1111/j.1601-0825.2000.tb00110.x
Smith, E. & Orholm, M. Trends and patterns of opportunistic diseases in Danish AIDS patients 1980–1990. Scand. J. Infect. Dis. 22, 665–672 (1990).
pubmed: 2135639
doi: 10.3109/00365549009027119
Buchacz, K. et al. AIDS-defining opportunistic illnesses in US patients, 1994–2007: A cohort study. AIDS 24, 1549–1559 (2010).
pubmed: 20502317
doi: 10.1097/QAD.0b013e32833a3967